Barrett Hodgson Pakistan (Pvt) Ltd is pleased to announce the launch of RosuBar
RosuBar (Rosuvastatin) is indicated as an adjunctive therapy to diet in order to reduce elevated Total Cholesterol, LDL, Apo B, non HDL & triglycerides and to increase HDL in adult patients with Primary Hyperlipidemia or mixed Dyslipidemia, RosuBar (Rosuvastatin) is also indicated as an adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients.
RosuBar is available as 5 mg, 10 mg & 20 mg tablet in pack of 10’s.
By introducing RosuBar (Rosuvastatin) Barrett Hodgson offers, yet another effective, economical and Quality product for the ailing humanity.